Literature DB >> 11352749

The loading module of rifamycin synthetase is an adenylation-thiolation didomain with substrate tolerance for substituted benzoates.

S J Admiraal1, C T Walsh, C Khosla.   

Abstract

The rifamycin synthetase is primed with a 3-amino-5-hydroxybenzoate starter unit by a loading module that contains domains homologous to the adenylation and thiolation domains of nonribosomal peptide synthetases. Adenylation and thiolation activities of the loading module were reconstituted in vitro and shown to be independent of coenzyme A, countering literature proposals that the loading module is a coenzyme A ligase. Kinetic parameters for covalent arylation of the loading module were measured directly for the unnatural substrates benzoate and 3-hydroxybenzoate. This analysis was extended through competition experiments to determine the relative rates of incorporation of a series of substituted benzoates. Our results show that the loading module can accept a variety of substituted benzoates, although it exhibits a preference for the 3-, 5-, and 3,5-disubstituted benzoates that most closely resemble its biological substrate. The considerable substrate tolerance of the loading module of rifamycin synthetase suggests that the module has potential as a tool for generating substituted derivatives of natural products.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352749     DOI: 10.1021/bi010080z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

Review 1.  Combinatorial biosynthesis--potential and problems.

Authors:  Heinz G Floss
Journal:  J Biotechnol       Date:  2006-01-18       Impact factor: 3.307

2.  Stereochemical assignment of intermediates in the rifamycin biosynthetic pathway by precursor-directed biosynthesis.

Authors:  Ingo V Hartung; Mathew A Rude; Nathan A Schnarr; Daniel Hunziker; Chaitan Khosla
Journal:  J Am Chem Soc       Date:  2005-08-17       Impact factor: 15.419

3.  Genetics and Genomics of the Genus Amycolatopsis.

Authors:  Rashmi Kumari; Priya Singh; Rup Lal
Journal:  Indian J Microbiol       Date:  2016-05-02       Impact factor: 2.461

Review 4.  Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis.

Authors:  Kuni Takayama; Cindy Wang; Gurdyal S Besra
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

5.  Whole genome sequence of the rifamycin B-producing strain Amycolatopsis mediterranei S699.

Authors:  Mansi Verma; Jaspreet Kaur; Mukesh Kumar; Kirti Kumari; Anjali Saxena; Shailly Anand; Aeshna Nigam; Vydianathan Ravi; Saurabh Raghuvanshi; Paramjit Khurana; Akhilesh K Tyagi; Jitendra P Khurana; Rup Lal
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

6.  Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis.

Authors:  Aeshna Nigam; Khaled H Almabruk; Anjali Saxena; Jongtae Yang; Udita Mukherjee; Hardeep Kaur; Puneet Kohli; Rashmi Kumari; Priya Singh; Lev N Zakharov; Yogendra Singh; Taifo Mahmud; Rup Lal
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

7.  Anthranilate-activating modules from fungal nonribosomal peptide assembly lines.

Authors:  Brian D Ames; Christopher T Walsh
Journal:  Biochemistry       Date:  2010-04-20       Impact factor: 3.162

8.  Priming type II polyketide synthases via a type II nonribosomal peptide synthetase mechanism.

Authors:  Miho Izumikawa; Qian Cheng; Bradley S Moore
Journal:  J Am Chem Soc       Date:  2006-02-08       Impact factor: 15.419

9.  Mycobacterial phenolic glycolipid virulence factor biosynthesis: mechanism and small-molecule inhibition of polyketide chain initiation.

Authors:  Julian A Ferreras; Karen L Stirrett; Xuequan Lu; Jae-Sang Ryu; Clifford E Soll; Derek S Tan; Luis E N Quadri
Journal:  Chem Biol       Date:  2007-12-27

10.  Engineered biosynthesis of an ansamycin polyketide precursor in Escherichia coli.

Authors:  Kenji Watanabe; Mathew A Rude; Christopher T Walsh; Chaitan Khosla
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.